When this was written — On 19 June 2026. The figures are as at that date or earlier and have not been updated since.
Pathology pricing pressures and post-pandemic volume normalisation have kept Australian Clinical Labs under pressure, but a recent 19.6% share price bounce over the last month suggests some buyers are stepping back in. The short sellers, however, are not buying the recovery.
While broader market sentiment has stalled with 11 neutral ratings over the last 30 days, inside tracking shows some buying. Director S Butler registered a buy on 20 February 2026 1, a lone positive mark against a backdrop of deteriorating sector sentiment. Despite this boardroom confidence, the broader market remains highly sceptical of the pathology sector's near-term margin recovery, especially as inflationary pressures on labour and collection centre rents continue to bite.
Short interest in the pathology firm has climbed to 8.21%, up 1.66 percentage points from its 90-day average of 6.55% and pushing past the peer sector average of 7.35%. This accumulation has occurred alongside a 19.6% price rally over the last month to $2.26, creating a negative 30-day price-to-short correlation of -0.234. The 30-day short slope of 0.0514 percentage points per day indicates a steady, deliberate accumulation rather than a sudden spike.
With short interest sitting just below its 90-day high of 8.61%, the tension between a rallying share price and rising short positions will eventually have to break.